Westerdijk K, Desar IME, Steeghs N, van der Graaf WTA, van Erp NP. Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol. 2020;86:258–73. https://doi.org/10.1111/bcp.14185.

Article  PubMed  PubMed Central  Google Scholar 

Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, et al. Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review. Ther Drug Monit. 2020;42:33. https://doi.org/10.1097/FTD.0000000000000699.

Article  PubMed  Google Scholar 

Josephs DH, Fisher DS, Spicer J, Flanagan RJ. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit. 2013;35:562. https://doi.org/10.1097/FTD.0b013e318292b931.

Article  CAS  PubMed  Google Scholar 

Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77:441–64. https://doi.org/10.1007/s00228-020-03014-8.

Article  PubMed  Google Scholar 

van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, et al. Tyrosine kinase inhibitors and proton pump inhibitors: an evaluation of treatment options. Clin Pharmacokinet. 2017;56:683–8. https://doi.org/10.1007/s40262-016-0503-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Le Louedec F, Puisset F, Chatelut E, Tod M. Considering the oral bioavailability of protein kinase inhibitors: essential in assessing the extent of drug-drug interaction and improving clinical practice. Clin Pharmacokinet. 2023;62:55–66. https://doi.org/10.1007/s40262-022-01200-8.

Article  PubMed  Google Scholar 

Puisset F, Mseddi M, Mourey L, Pouessel D, Blanchet B, Chatelut E, et al. Therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of advanced renal cancer. Cancers (Basel). 2023;15:313. https://doi.org/10.3390/cancers15010313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007;6:734–45. https://doi.org/10.1038/nrd2380.

Article  CAS  PubMed  Google Scholar 

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909–16. https://doi.org/10.1038/bjc.2014.503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit. 2015;37:331–8. https://doi.org/10.1097/FTD.0000000000000141.

Article  CAS  PubMed  Google Scholar 

Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, et al. Model-informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;215:115421. https://doi.org/10.1016/j.addr.2024.115421.

Article  CAS  PubMed  Google Scholar 

Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes DJAR, et al. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study. Ann Oncol. 2022;33:1071–82. https://doi.org/10.1016/j.annonc.2022.06.010.

Article  CAS  PubMed  Google Scholar 

Janssen JM, Dorlo TPC, Beijnen JH, Huitema ADR. Evaluation of extrapolation methods to predict trough concentrations to guide therapeutic drug monitoring of oral anticancer drugs. Ther Drug Monit. 2020;42:532–9. https://doi.org/10.1097/FTD.0000000000000767.

Article  PubMed  Google Scholar 

Buclin T, Thoma Y, Widmer N, André P, Guidi M, Csajka C, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with Imatinib. Front Pharmacol. 2020;11:177. https://doi.org/10.3389/fphar.2020.00177.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacomet Syst Pharmacol. 2018;7:785–7. https://doi.org/10.1002/psp4.12353.

Article  CAS  Google Scholar 

Kluwe F, Michelet R, Mueller-Schoell A, Maier C, Klopp-Schulze L, van Dyk M, et al. Perspectives on model-informed precision dosing in the digital health era: challenges, opportunities, and recommendations. Clin Pharmacol Ther. 2021;109:29–36. https://doi.org/10.1002/cpt.2049.

Article  PubMed  Google Scholar 

Wicha SG, Märtson A-G, Nielsen EI, Koch BCP, Friberg LE, Alffenaar J-W, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109:928–41. https://doi.org/10.1002/cpt.2202.

Article  CAS  PubMed  Google Scholar 

Uster DW, Stocker SL, Carland JE, Brett J, Marriott DJE, Day RO, et al. A model averaging/selection approach improves the predictive performance of model-informed precision dosing: vancomycin as a case study. Clin Pharmacol Ther. 2021;109:175–83. https://doi.org/10.1002/cpt.2065.

Article  CAS  PubMed  Google Scholar 

Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J, et al. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacomet Syst Pharmacol. 2022;11:1045–59. https://doi.org/10.1002/psp4.12813.

Article  CAS  Google Scholar 

Hughes JH, Keizer RJ. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacomet Syst Pharmacol. 2021;10:1150–60. https://doi.org/10.1002/psp4.12684.

Article  CAS  Google Scholar 

Yang Y, Wang C, Chen Y, Wang X, Jiao Z, Wang Z. External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients. Eur J Pharm Sci. 2023;186:106416. https://doi.org/10.1016/j.ejps.2023.106416.

Article  CAS  PubMed  Google Scholar 

Broeker A, Nardecchia M, Klinker KP, Derendorf H, Day RO, Marriott DJ, et al. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting. Clin Microbiol Infect. 2019;25:1286.e1-1286.e7. https://doi.org/10.1016/j.cmi.2019.02.029.

Article  CAS  PubMed  Google Scholar 

Ter Heine R, Keizer RJ, van Steeg K, Smolders EJ, van Luin M, Derijks HJ, et al. Prospective validation of a model-informed precision dosing tool for vancomycin in intensive care patients. Br J Clin Pharmacol. 2020;86:2497–506. https://doi.org/10.1111/bcp.14360.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, et al. Therapeutic drug monitoring of imatinib. Clin Pharmacokinet. 2012;51:187–201. https://doi.org/10.2165/11596990-000000000-00000.

Article  CAS  PubMed  Google Scholar 

European Medecines Agency. Sutent: EPAR—product information. Annex I—summary of product characteristics. Amsterdam: EMA; 2009 [cited 2019 Jul 23]. https://www.ema.europa.eu/documents/product-information/sutent-epar-product-information_en.pdf. Accessed 23 Jul 2019.

European Medecines Agency. Votrient : EPAR—product Information. Annex I—summary of product characteristics. Amsterdam: EMA; 2010 [cited 2019 Jul 23]. https://www.ema.europa.eu/en/documents/product-information/votrient-epar-product-information_en.pdf. Accessed 23 Jul 2019.

Paludetto M-N, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, et al. Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS. J Pharm Biomed Anal. 2018;154:373–83. https://doi.org/10.1016/j.jpba.2018.03.013.

Article  CAS  PubMed  Google Scholar 

Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15:2497–506. https://doi.org/10.1158/1078-0432.CCR-08-1893.

Article  CAS  PubMed  Google Scholar 

Khosravan R, Motzer RJ, Fumagalli E, Rini BI. Population pharmacokinetic/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor. Clin Pharmacokinet. 2016;55:1251–69. https://doi.org/10.1007/s40262-016-0404-5.

Article